SCHEMBL4325354

SCHEMBL4325354

O=S(=O)(Cl)c1cccc2ncccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
CYP3A4 P08684 2/20 0.54
NFKB1 P19838 1/20 0.54
THPO P40225 1/20 0.54
HIF1A Q16665 1/20 0.54
LMNA P02545 4/20 0.52
MAPT P10636 2/20 0.52
BLM P54132 1/20 0.52
KDM4E B2RXH2 1/20 0.48
TRPV4 Q9HBA0 1/20 0.46
POLB P06746 1/20 0.46
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
CA12 O43570 2/20 0.45
PABPC1 P11940 2/20 0.45
EIF4H Q15056 2/20 0.45
HTT P42858 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30871757 0.98 LMNA (0.55) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL11043739 0.87 NCF1 (0.47) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL5243080 0.81 COMT (0.56) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL11681357 0.81 TSHR (0.54) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL10050955 0.81 PABPC1 (0.58) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL1626273 0.81 CA2 (0.56) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL27419573 0.80 TRPV4 (0.51) TSHRCYP3A4NFKB1THPOHIF1A
Iodide SCHEMBL29914016 0.80 COMT (0.54) TSHRCYP3A4NFKB1THPOHIF1A
SCHEMBL22050086 0.80 COMT (0.55) TSHRCYP3A4NFKB1THPOHIF1A
Water SCHEMBL21625620 0.80 COMT (0.54) TSHRCYP3A4NFKB1THPOHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102690259-B Compound with function of diuresis, preparation method and functions thereof TIANJIN INST PHARM RESEARCH 2014-05-28 CN claimed
CN-102942558-B Preparation method of benzazepine derivatives TIANJIN INST PHARM RESEARCH 2014-04-16 CN claimed
CN-102942558-A Preparation method of benzazepine derivatives TIANJIN INST PHARM RESEARCH 2013-02-27 CN claimed
CN-102690259-A Compound with function of diuresis, preparation method and functions thereof TIANJIN INST PHARM RESEARCH 2012-09-26 CN claimed
CN-121085840-A Preparation method of medicine intermediate 2-amino-3-hydroxypyridine 辽宁中舟得水环保科技有限公司 2025-12-09 CN disclosed
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 US disclosed
CN-119409685-B 4- (1- (Azaacyl-3-butyl) -1H-imidazol-2-yl) anilides PKM2 agonists 南京医科大学 2025-04-25 CN disclosed
CN-119409685-A 4- (1- (Azaacyl-3-butyl) -1H-imidazol-2-yl) anilides PKM2 agonists 南京医科大学 2025-02-11 CN disclosed
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS VANDERBILT UNIVERSITY 2023-09-28 US disclosed
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS VANDERBILT UNIVERSITY 2023-09-28 US disclosed
WO-2005049023-A1 GLYT1 TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed
WO-2005049023-A1 GLYT1 TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed
EP-1455777-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM PLC (GB) 2004-09-15 EP disclosed
WO-2003055478-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-10 WO disclosed
US-6271247-B1 BINDING TO NEUROPEPTIDE RECEPTORS ADIR ET COMPAGNIE (FR) 2001-08-07 US disclosed
EP-0471841-B1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 1995-11-02 EP disclosed
US-5340811-A Bronchodilator agent ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1994-08-23 US disclosed
EP-0471841-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1992-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 TSHR 3378/4885CYP3A4 2646/4885NFKB1 1771/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 TSHR 3378/4885CYP3A4 2646/4885NFKB1 1771/4885
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS CHRM5, CHRM1, CHRM2 TSHR 52/4885CYP3A4 641/4885NFKB1 3307/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 TSHR 3378/4885CYP3A4 2646/4885NFKB1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.